Journey Medical Corporation Stock

Equities

DERM

US48115J1097

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-05-03 pm EDT 5-day change 1st Jan Change
3.69 USD +1.65% Intraday chart for Journey Medical Corporation +8.53% -35.94%
Sales 2024 * 58.01M Sales 2025 * 82.04M Capitalization 73.7M
Net income 2024 * -15M Net income 2025 * -4M EV / Sales 2024 * 1.27 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.9 x
P/E ratio 2024 *
-4.99 x
P/E ratio 2025 *
-18.5 x
Employees 41
Yield 2024 *
-
Yield 2025 *
-
Free-Float 49.09%
More Fundamentals * Assessed data
Dynamic Chart
Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer CI
Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea CI
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting CI
Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target MT
Journey Medical Submits New Drug Application to FDA for Rosacea Treatment; Shares Rise MT
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea CI
Journey Medical Signs Credit Facility of up to $20 Million MT
Journey Medical Corporation Secures Credit Facility with SWK Holdings for Up to $20 Million CI
Journey Medical Corporation Announces Resignation of Jeffrey Paley as Member of the Board of Directors CI
B. Riley Lifts Journey Medical's PT to $8 From $6 After US FDA Gives Green Light for DFD-29's Year-End 2023 Filing, Keeps Buy Rating MT
Journey Medical Corporation Announces Successful Completion of Pre-Nda Meeting with the Fda for Dfd-29 to Treat Rosacea CI
Journey Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Journey Medical Corporation, Q3 2023 Earnings Call, Nov 07, 2023
More news

Latest transcript on Journey Medical Corporation

1 day+1.65%
1 week+8.53%
1 month-15.37%
3 months-23.44%
6 months+6.96%
Current year-35.94%
More quotes
1 week
3.27
Extreme 3.265
3.73
1 month
3.27
Extreme 3.265
4.64
Current year
2.85
Extreme 2.85
6.15
1 year
1.02
Extreme 1.02
8.11
3 years
1.02
Extreme 1.02
10.20
5 years
1.02
Extreme 1.02
10.20
10 years
1.02
Extreme 1.02
10.20
More quotes
Managers TitleAgeSince
Founder 57 14-09-30
Director of Finance/CFO 57 21-10-31
Chief Tech/Sci/R&D Officer - 21-08-31
Members of the board TitleAgeSince
Chairman 68 14-09-30
Director/Board Member 67 20-12-31
Director/Board Member 47 21-04-30
More insiders
Date Price Change Volume
24-05-03 3.69 +1.65% 51,784
24-05-02 3.63 +3.42% 47,993
24-05-01 3.51 -4.88% 62,515
24-04-30 3.69 +10.81% 98,295
24-04-29 3.33 -2.06% 141,312

Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT

More quotes
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.69 USD
Average target price
8.25 USD
Spread / Average Target
+123.58%
Consensus